Approval · Notice of Compliance 10225 · 2009
STRATTERA: Notice of Compliance 10225
Issued May 25, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10225
- Date
- May 25, 2009
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revision to the Dosage and Administration section and other revisions to the Product Monograph
- Therapeutic class
- Selective norepinephrine reuptake inhibitor for attention-deficit/hyperactivity disorder (adhd)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| STRATTERA | Not yet assigned | — |
Medicinal ingredients
- ATOMOXETINE HYDROCHLORIDE 10 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 18 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 25 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 40 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 60 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 80 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 100 MG per CAP